189 related articles for article (PubMed ID: 20518890)
1. 9p21 deletion in the diagnosis of malignant mesothelioma, using fluorescence in situ hybridization analysis.
Takeda M; Kasai T; Enomoto Y; Takano M; Morita K; Kadota E; Nonomura A
Pathol Int; 2010 May; 60(5):395-9. PubMed ID: 20518890
[TBL] [Abstract][Full Text] [Related]
2. Diagnostic importance of 9p21 homozygous deletion in malignant mesotheliomas.
Chiosea S; Krasinskas A; Cagle PT; Mitchell KA; Zander DS; Dacic S
Mod Pathol; 2008 Jun; 21(6):742-7. PubMed ID: 18327208
[TBL] [Abstract][Full Text] [Related]
3. The diagnostic utility of p16 FISH and GLUT-1 immunohistochemical analysis in mesothelial proliferations.
Monaco SE; Shuai Y; Bansal M; Krasinskas AM; Dacic S
Am J Clin Pathol; 2011 Apr; 135(4):619-27. PubMed ID: 21411785
[TBL] [Abstract][Full Text] [Related]
4. The importance of FISH signal cut-off values for 9p21 deletion in malignant pleural mesothelioma: Is it underestimated?
Kulduk G; Ekinci Ö; Toker G; Demirci U; Özaydın E; Akyürek N; Memiş L
Pathol Res Pract; 2019 Jun; 215(6):152377. PubMed ID: 30885529
[TBL] [Abstract][Full Text] [Related]
5. Morphology of 9p21 homozygous deletion-positive pleural mesothelioma cells analyzed using fluorescence in situ hybridization and virtual microscope system in effusion cytology.
Matsumoto S; Nabeshima K; Kamei T; Hiroshima K; Kawahara K; Hata S; Marukawa K; Matsuno Y; Taguchi K; Tsujimura T
Cancer Cytopathol; 2013 Aug; 121(8):415-22. PubMed ID: 23450849
[TBL] [Abstract][Full Text] [Related]
6. Adaptation of a commercial fluorescent in situ hybridization test to the diagnosis of malignant cells in effusions.
Flores-Staino C; Darai-Ramqvist E; Dobra K; Hjerpe A
Lung Cancer; 2010 Apr; 68(1):39-43. PubMed ID: 19523712
[TBL] [Abstract][Full Text] [Related]
7. 9p21 Deletion in the diagnosis of malignant mesothelioma in serous effusions additional to immunocytochemistry, DNA-ICM, and AgNOR analysis.
Onofre FB; Onofre AS; Pomjanski N; Buckstegge B; Grote HJ; Böcking A
Cancer; 2008 Jun; 114(3):204-15. PubMed ID: 18306350
[TBL] [Abstract][Full Text] [Related]
8. The use of CDKN2A deletion as a diagnostic marker for malignant mesothelioma in body cavity effusions.
Illei PB; Ladanyi M; Rusch VW; Zakowski MF
Cancer; 2003 Feb; 99(1):51-6. PubMed ID: 12589646
[TBL] [Abstract][Full Text] [Related]
9. Comparison of genomic abnormality in malignant mesothelioma by the site of origin.
Takeda M; Kasai T; Enomoto Y; Takano M; Morita K; Nakai T; Iizuka N; Maruyama H; Ohbayashi C
J Clin Pathol; 2014 Dec; 67(12):1038-43. PubMed ID: 25217709
[TBL] [Abstract][Full Text] [Related]
10. Genomic gains and losses in malignant mesothelioma demonstrated by FISH analysis of paraffin-embedded tissues.
Takeda M; Kasai T; Enomoto Y; Takano M; Morita K; Kadota E; Iizuka N; Maruyama H; Nonomura A
J Clin Pathol; 2012 Jan; 65(1):77-82. PubMed ID: 22081786
[TBL] [Abstract][Full Text] [Related]
11. Homozygous deletion of CDKN2A and codeletion of the methylthioadenosine phosphorylase gene in the majority of pleural mesotheliomas.
Illei PB; Rusch VW; Zakowski MF; Ladanyi M
Clin Cancer Res; 2003 Jun; 9(6):2108-13. PubMed ID: 12796375
[TBL] [Abstract][Full Text] [Related]
12. p16/CDKN2A FISH in Differentiation of Diffuse Malignant Peritoneal Mesothelioma From Mesothelial Hyperplasia and Epithelial Ovarian Cancer.
Ito T; Hamasaki M; Matsumoto S; Hiroshima K; Tsujimura T; Kawai T; Shimao Y; Marutsuka K; Moriguchi S; Maruyama R; Miyamoto S; Nabeshima K
Am J Clin Pathol; 2015 Jun; 143(6):830-8. PubMed ID: 25972325
[TBL] [Abstract][Full Text] [Related]
13. A comparison of epidermal growth factor receptor expression in malignant peritoneal and pleural mesothelioma.
Enomoto Y; Kasai T; Takeda M; Takano M; Morita K; Kadota E; Iizuka N; Maruyama H; Haratake J; Kojima Y; Ikeda N; Nonomura A
Pathol Int; 2012 Apr; 62(4):226-31. PubMed ID: 22449226
[TBL] [Abstract][Full Text] [Related]
14. Hemizygous loss of NF2 detected by fluorescence in situ hybridization is useful for the diagnosis of malignant pleural mesothelioma.
Kinoshita Y; Hamasaki M; Yoshimura M; Matsumoto S; Iwasaki A; Nabeshima K
Mod Pathol; 2020 Feb; 33(2):235-244. PubMed ID: 31231129
[TBL] [Abstract][Full Text] [Related]
15. p16 FISH deletion in surface epithelial mesothelial proliferations is predictive of underlying invasive mesothelioma.
Hwang H; Tse C; Rodriguez S; Gown A; Churg A
Am J Surg Pathol; 2014 May; 38(5):681-8. PubMed ID: 24503757
[TBL] [Abstract][Full Text] [Related]
16. [Detection of p16 by fluorescence in-situ hybridization and immunohistochemistry in malignant mesothelioma].
Liu Y; Chen X; Ding N; Xu W; Yang H; Chen X
Zhonghua Bing Li Xue Za Zhi; 2015 Apr; 44(4):262-5. PubMed ID: 25975910
[TBL] [Abstract][Full Text] [Related]
17. Malignant mesothelioma: immunohistochemistry and DNA ploidy analysis as methods to differentiate mesothelioma from benign reactive mesothelial cell proliferation and adenocarcinoma in pleural and peritoneal effusions.
Friedman MT; Gentile P; Tarectecan A; Fuchs A
Arch Pathol Lab Med; 1996 Oct; 120(10):959-66. PubMed ID: 12046609
[TBL] [Abstract][Full Text] [Related]
18. Immunohistochemical detection of MTAP and BAP1 protein loss for mesothelioma diagnosis: Comparison with 9p21 FISH and BAP1 immunohistochemistry.
Hida T; Hamasaki M; Matsumoto S; Sato A; Tsujimura T; Kawahara K; Iwasaki A; Okamoto T; Oda Y; Honda H; Nabeshima K
Lung Cancer; 2017 Feb; 104():98-105. PubMed ID: 28213009
[TBL] [Abstract][Full Text] [Related]
19. Implications of P16/CDKN2A deletion in pleural mesotheliomas.
Ladanyi M
Lung Cancer; 2005 Jul; 49 Suppl 1():S95-8. PubMed ID: 15950811
[TBL] [Abstract][Full Text] [Related]
20. Polysomy and p16 deletion by fluorescence in situ hybridization in the diagnosis of indeterminate biliary strictures.
Gonda TA; Glick MP; Sethi A; Poneros JM; Palmas W; Iqbal S; Gonzalez S; Nandula SV; Emond JC; Brown RS; Murty VV; Stevens PD
Gastrointest Endosc; 2012 Jan; 75(1):74-9. PubMed ID: 22100297
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]